Inovio Pharmaceuticals Inc vs Sasol Ltd. American Depositary Shares — how do they compare? Inovio Pharmaceuticals Inc trades at $1.11 (market cap $112.19M), while Sasol Ltd. American Depositary Shares trades at $15.13 (market cap $9.69B). The key difference: Sasol Ltd. American Depositary Shares is far larger — about 86.4× Inovio Pharmaceuticals Inc's market cap, and Sasol Ltd. American Depositary Shares is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Sasol Ltd. American Depositary Shares for 0 Days on average.
| INO | SSL | |
|---|---|---|
Market Cap | $112.19M | $9.69B |
Volume | 3,201,278 | 2,297,057 |
Sector | Health | Basic Materials |
52-Week High | $2.65 | $15.14 |
52-Week Low | $0.66 | $5.33 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $83.51M | $13.39B |
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Sasol Limited is a Johannesburg-headquartered chemicals and energy company that uses its proprietary Fischer-Tropsch technology to convert coal, natural gas, and crude-oil feedstocks into fuels and chemical products such as polymers, solvents, surfactants, and ammonia, with operations across Southern Africa and international chemical manufacturing sites, including in US.
Read more on SSL →